# Maternal transmission of Alzheimer's disease: Prodromal metabolic phenotype and the search for genes

**Lisa Mosconi**[1,*], **Valentina Berti**[2], **Russell H. Swerdlow**[3], **Alberto Pupi**[2], **Ranjan Duara**[4], and **Mony de Leon**[1,5]

[1]Center for Brain Health, New York University School of Medicine, New York, NY 10016, USA

[2]Nuclear Medicine Unit, University of Florence, Careggi Hospital, 50134 Florence, Italy

[3]Landon Center on Aging, MS2012, Kansas City, KS 66160-7401, USA

[4]Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, and Miller School of Medicine, University of Miami, Miami, FL 33140, USA

[5]Nathan Kline Institute, Orangeburg, NY 1096, USA

## Abstract

After advanced age, having a parent affected with Alzheimer's disease (AD) is the most significant risk factor for developing AD among cognitively normal (NL) individuals. Although rare genetic mutations have been identified among the early-onset forms of familial AD (EOFAD), the genetics of the more common forms of late-onset AD (LOAD) remain elusive. While some LOAD cases appear to be sporadic in nature, genetically mediated risk is evident from the familial aggregation of many LOAD cases. The patterns of transmission and biological mechanisms through which a family history of LOAD confers risk to the offspring are not known. Brain imaging studies using 2-[$^{18}$F]fluoro-2-deoxy-D-glucose positron emission tomography ($^{18}$F-FDG PET) have shown that NL individuals with a maternal history of LOAD, but not with a paternal family history, express a phenotype characterised by a pattern of progressive reductions of brain glucose metabolism, similar to that in AD patients. As maternally inherited AD may be associated with as many as 20 per cent of the total LOAD population, understanding the causes and mechanisms of expression of this form of AD is of great relevance. This paper reviews known genetic mutations implicated in EOFAD and their effects on brain chemistry, structure and function; epidemiology and clinical research findings in LOAD, including *in vivo* imaging findings showing selective patterns of hypometabolism in maternally inherited AD; possible genetic mechanisms involved in maternal transmission of AD, including chromosome X mutations, mitochondrial DNA and imprinting; and genetic mechanisms involved in other neurological disorders with known or suspected maternal inheritance. The review concludes with a discussion of the potential role of brain imaging for identifying endophenotypes in NL individuals at risk for AD, and for directing investigation of potential susceptibility genes for AD.

## Keywords

*Correspondence to*: Tel: +1 212 263 3255; Fax: +1 212 263 3270; lisa.mosconi@nyumc.org .

## Alzheimer's disease: Incidence and clinical profile

Alzheimer's disease (AD) is the most common form of dementia in late life, affecting approximately 10 per cent of individuals of 65 years of age, with the prevalence doubling every five years up to the age of 80, above which the prevalence is 40 per cent.[1] In 2008, in the United States alone, there were more than 5 million people with AD, which is a 10 per cent increase from the previous (in 2000) prevalence estimate of 4.5 million (Figure 1, adapted from Hebert *et al.*[2]). Age-related mild cognitive impairments may affect two to three times as many individuals.[3,4] By 2050, the number of elderly people with AD in the USA could range from 11 million to 16 million, which strongly calls for strategies to prevent or delay the onset of the disease.

AD is a neurodegenerative disorder characterised by global deficits in cognition, ranging from memory loss to impaired judgment and reasoning.[5] Clinical diagnosis *per se* is often uncertain and clinical assessment requires multiple examinations and laboratory tests over time. Despite thorough clinical exams, the frequency of unrecognised dementia in the community ranges from 50 per cent to 90 per cent of cases.[6] Insidious onset and progressive impairment of memory and other cognitive functions make the initial stages of AD difficult to distinguish from so called 'normal ageing'. In order to develop prevention treatments for AD, it is necessary to identify persons who are still cognitively normal (NL), but are either at very high risk for developing the disease or are in an early, pre-symptomatic stage of the disease. Such individuals are most likely to benefit from therapies which are instituted when the potential for preservation of function is the greatest, well before irreversible synaptic and neuronal injury.

The difficulty in studying the genetics of complex, age-associated disorders such as late onset AD (LOAD) using traditional clinical case identification measures has resulted in an increasing emphasis on studying endophenotypes of AD, which provide more specific targets for genetic studies. In 2007, it was shown that NL children of mothers affected with LOAD express a biological phenotype characterised by progressive reductions in brain glucose metabolism in the same brain regions as clinical AD patients, as measured on 2-[$^{18}$F]fluoro-2-deoxy–D–glucose positron emission tomography ($^{18}$F-FDG PET).[7] By contrast, children of AD-affected fathers and of parents with no dementia did not show metabolic abnormalities.[7] The genetic basis for the selective maternal transmission of metabolic deficits in AD is not known.

The present review first summarises known genetic mechanisms involved in the early- and late-onset forms of AD, and *in vivo* brain imaging studies that provide a link between genetics, pathology and pathophysiology in AD. It then presents recent findings of progressive reductions in brain glucose metabolism in adult children of mothers affected with LOAD, and discusses possible genetic and epigenetic mechanisms involved in maternally inherited brain hypometabolism. Finally, it examines other neurological disorders with known or suspected maternal transmission, and discusses the role of imaging in identifying endophenotypes in preclinical AD.

Although many imaging methods are available, this review will focus on the two most widely utilised brain imaging techniques in both clinical practice and research studies in AD — magnetic resonance imaging (MRI) and PET. Various MRI and PET studies in AD have been published recently.[8-13] Briefly, these methods have long been used in AD for the detection of structural brain changes and volume reductions due to neuronal loss (ie atrophy) on MRI, and reductions of cerebral metabolic rate of glucose (CMRglc) on $^{18}$F-FDG-PET. Both modalities accurately discriminate AD from controls, predict decline from normal cognition to dementia and correlate with disease progression and histopathological

diagnosis.[8-13] In addition, ^{18}F-FDG-PET has the advantage of being particularly useful for distinguishing AD from other forms of dementia.[10-13] Overall, AD patients present with brain atrophy and hypometabolism in the parieto-temporal, posterior cingulate, medial temporal and prefrontal cortex, while the primary motor and visual areas, cerebellum, thalamus and basal ganglia are relatively spared.[8-13]

In addition to traditional imaging techniques, a turning point in AD was accomplished with the recent development of PET tracers for amyloidbeta (Aβ) plaques, which allow examination of Aβ deposits *in vivo*. Among different amyloid PET ligands, the best characterised is the *N*-methyl-[^{11}C]2-(4′-methylaminophenyl)-6-hydroxybenzothiazole, also known as Pittsburgh compound-B (^{11}C-PIB).[14] AD patients consistently show ^{11}C-PIB uptake in amyloid-rich brain regions, particularly in the frontal, parieto-temporal, posterior cingulate, precuneus and occipital cortices, as well as the thalamus and striatum, whereas the control population mostly showed non-specific binding restricted to the white matter. [8,15,16-18] A combination of imaging modalities may help to make an earlier diagnosis, and to define the nature and extent of AD pathology among pre-symptomatic individuals.

## Autosomal dominant genetic transmission of AD: The early-onset forms

### The three genes that are causative of AD

A central role for Aβ in AD is strongly supported by studies of the rare early-onset (<60 years) forms of familial AD (EOFAD). Genetic factors that have been firmly implicated in EOFAD are mutations in the amyloid precursor protein (*APP*), presenilin 1 (*PSEN1*) and presenilin 2 (*PSEN2*) genes, which are found in large multi-generational families with an autosomal dominant pattern of disease inheritance. Major findings from studies of EOFAD mutation carriers are summarised in Table 1.

In 1990, the first mutation in the gene encoding APP, on chromosome 21, was discovered in a pedigree with Dutch-type hereditary cerebral haemorrhage with amyloidosis. Shortly after, a missense mutation occurring in the same *APP* exon (exon 17) was detected in patients with EOFAD.[19,20] Although *APP* mutations account for less than 0.1 per cent of all AD cases, they have virtually complete penetrance.[19,20] Only a year later, a second EOFAD locus was linked to chromosome 14, and the gene was later identified as *PSEN1*.[20] *PSEN1* is fully penetrant, has an age of onset of disease between 28 and 65 years and is responsible for the majority of EOFAD mutations identified thus far. A second presenilin gene (*PSEN2*), on chromosome 1, is responsible for six other EOFAD mutations. On average, EOFAD mutations in *PSEN2* exhibit a later age of onset of disease (ranging from 43 to 80 years) than those in *APP* or *PSEN1*.[19,20]

### The pathophysiology associated with EOFAD genes

Studies of the effects of these genetic mutations suggested a central role for Aβ in the pathogenesis of AD. Definitive diagnosis of AD requires postmortem observation of specific pathological lesions: Aβ plaques, neurofibrillary tangles (NFT) containing hyperphosphorylated tau protein, synaptic loss and brain atrophy in specific brain areas.[21,22]

EOFAD mutations in the *APP* and *PSEN* genes generally shift the processing of APP to Aβ$_{42}$, leading to an increased ratio of Aβ$_{42}$ to Aβ$_{40}$ (Table 1).[20] At post-mortem, EOFAD cases consistently show substantial AD pathology — particularly diffuse and numerous Aβ plaques surrounded by activated microglia — associated with extensive synaptic loss and brain atrophy.[20] Aβ peptides are formed from APP and cluster into amyloid plaques on the blood vessels and in the extraneuronal space.[23,24] Aβ peptides are toxic to cell cultures.[25,26] Ageing appears to render the brain more vulnerable to Aβ toxicity,[27] and Aβ further impairs mitochondrial function in ageing brains and initiates a neurotoxic cascade with parallel

overproduction of free radicals.[28] In AD, Aβ pathology was shown to occur upstream of tau pathology, and recent studies have shown that Aβ may lead to NFT formation within cells.[29] Nonetheless, a causal relationship between Aβ and tau pathology in AD remains to be clarified.

Clinically, EOFAD is characterised by a specific age of onset of cognitive impairment for a given pedigree. Therefore, studies of pre-symptomatic mutation carriers close to the expected age of onset provide unique information about preclinical AD-related brain changes. Asymptomatic and symptomatic *PSEN1* mutation carriers showed significant reductions in brain tissue (ie atrophy) on MRI and in global CMRglc on FDG-PET, as compared with age-matched controls.[30] CMRglc reductions on FDG-PET were shown to exceed MRI volume loss in pre-symptomatic *PSEN1* carriers.[31]

Amyloid imaging with ^{11}C-PIB PET showed higher amyloid load in both asymptomatic and symptomatic individuals carrying *PSEN1* mutations compared with controls.[32] ^{11}C-PIB retention was especially high in the striatum of all *PSEN1* mutation carriers compared with controls and sporadic AD patients. Symptomatic mutation carriers showed significant tracer retention also in the cortical regions, although uptake was not as high as in sporadic AD subjects.[32] These findings suggest that amyloid deposition in *PSEN1* mutation carriers may begin in the striatum before the onset of symptoms, and later spread to neocortical regions. [32,33] The data may also point to different patterns of Aβ deposition in AD, however, with the striatum being more affected in EOFAD and the cortex being more affected in the late-onset forms. A similar pattern of prominent ^{11}C-PIB retention in the striatum, especially in the caudate nucleus and putamen, was also found in EOFAD patients with *APP* mutations.[34]

### *APP* recessive mutations

While most studies demonstrated an association between autosomal dominant *APP* mutations and EOFAD forms, a recent study identified a mutation in the *APP* gene (*A673V*) that causes AD only in the homozygous state, reflecting recessive Mendelian inheritance.[35] Affected carriers presented at 36 years of age with behavioural changes and cognitive deficits, leading to severe dementia, spastic tetraparesis and a complete loss of autonomy.[35] This *APP* mutation was shown *in vitro* to have two pathogenic effects: shifting of APP processing toward the amyloidogenic pathway and enhancement of the aggregation of fibrillogenic Aβ.[35] Among heterozygotes, the interaction between wild-type and mutant Aβ produced by the non-mutated and mutated alleles appeared to hinder amyloidogenesis and neurotoxicity, thus protecting heterozygous carriers from developing the clinical syndrome.

Another homozygous *APP* mutation (*A693D*) resulted in clinical AD among three AD patients from a Japanese pedigree.[36] A heterozygous member of the same family was found to have mild cognitive impairment (MCI), which may lead to AD.[36] It remains to be established whether *A693D* is a recessive mutation or a dominant *APP* variant with incomplete penetrance.

## LOAD and the role of risk-modifying genes

The lesson learned from studying *APP* and *PSEN* mutations is that Aβ dysmetabolism may be a primary event in the pathogenesis of EOFAD. Whether this mechanism of action of Aβ leads to the more common, late-onset forms of AD remains to be determined. While the rare EOFAD cases have autosomal dominant inheritance and the onset and progression of the disease appears relatively independent of non-genetic factors, LOAD, which comprises 99 per cent of the AD population after the age of 60, does not seem to be associated with clearly discernible nuclear genetic mutations. Several genetic and non-genetic factors influence the risk for the development of LOAD and modify both the age at onset and the

course of the disease. These include genes (predisposing risk alleles), sociodemographic background (education, intellectual engagement), lifestyle (diet, fitness), environment and medical history (head trauma, medications, smoking, vascular diseases, etc).

Studies of monozygotic (MZ) and dizygotic (DZ) twins affected by LOAD suggest that genetic influence may predominate over environmental influence.[37,38] In a twin study, a twin pair can either be concordant (both individuals have the disorder) or discordant (only one of two is affected). MZ twins share all of their chromosomes, while DZ twins do not. Therefore, evidence that MZ twins are more concordant for AD than DZ twins would indicate stronger genetic influence. Evidence for the role of the environment comes from MZ twins who are discordant for the disease. Results from Swedish and Finnish twin registries have shown high rates of concordance for AD (over 80 per cent for MZ and 46 per cent for DZ) and high heritability (≥74 per cent).[38,39] Genetic influence on the age of onset of AD is demonstrated by the fact that it was more concordant for MZ compared with DZ twin pairs.[38]

The challenge in identifying genetic factors involved in LOAD may be due to a combination of variables, which include its insidious onset and slow progression, the complexity of most age-related conditions, the variable influence of various environmental and medical conditions often over a period of decades and the lack of sensitive and specific criteria for incipient AD. Because it is necessary for other family members to survive until the age of onset of the disease, cases may not be recognised as being familial. Genetic association studies in LOAD have identified single DNA sequence variations within a single nucleotide —that is, single nucleotide polymorphisms (SNPs; these are DNA sequence variations that occur when a single nucleotide [A, T, C or G] in the genome sequence is altered) or haplotypes (ie a combination of alleles at multiple loci that are transmitted together on the same chromosome, or can be defined as a set of SNPs on a single chromosome that are statistically associated)—that are associated with increased risk. Although several SNPs within specific genes have been reported to be associated with LOAD, this review will focus on more widely studied polymorphisms in five genes: apolipoprotein E (*ApoE*), sortilin-related receptor 1 (*SORL1*), growth factor receptor bound (GRB)-associated binding protein 2 (*GAB2*), protocadherin 11 (*PCDH11X*) and kidney and brain (*KIBRA*) genes. Major findings from studies of susceptibility genes involved with LOAD are summarised in Table 1.

## ApoE

In 1993, Strittmatter and colleagues discovered that carriers of the epsilon 4 (*ε*4) allele of the gene encoding ApoE, located on chromosome 19, are at higher risk for AD than non-carriers.[40] ApoE contains two SNPs that result in three possible alleles for this gene: *ε*2, *ε*3 and *ε*4. Each allele differs by one DNA base, and the protein product of each gene differs by one amino acid. Case-control studies showed that the *ApoE ε4* genotype occurs in approximately 40 per cent of all LOAD patients and is also over-represented in EOFAD.[19] Animal and human studies suggest that the association of the *ApoE ε4* allele with AD is mediated primarily by a dose-dependent effect of the *ε*4 allele on the deposition of Aβ in the brain.[41-45] Some have speculated that ApoE may also influence AD risk by disrupting microtubule-associated tau protein metabolism.[19,46]

MRI studies have demonstrated an association between the *ε*4 allele and hippocampal atrophy, with the rate of hippocampal volume loss being greater for the *ε*4 carriers than for the non-carriers.[47,48] 18F-FDG PET studies showed that, compared with non-carriers, asymptomatic carriers of the *ApoE ε4* genotype show CMRglc reductions within the brain regions typically affected in clinical AD patients.[49] They also showed greater CMRglc declines over time.[49] Despite its well-established association with AD, the *ApoE ε4*

genotype has no clear familial pattern of transmission and appears to act as a risk modifier by lowering the age at onset of clinical symptoms, rather than as a causal determinant. [19,50-52].

## SORL1

Recent studies have shown an association between *SORL1*, located on chromosome 11, and LOAD. Genetic changes in *SORL1* expression appear to be causally linked to the pathogenesis of AD and to increased risk for the disease.[53] In particular, SNPs in different regions of *SORL1* were associated with AD in multiple ethnically diverse samples[53-55] and also in the Translational Genomics Research Institute (TGEN) database.[56] Evidence for various AD-associated haplotypes supports the notion that there may be a high degree of allelic heterogeneity, with disease-associated variants occurring on multiple different haplotypic backgrounds.

*SORL1* encodes a protein that modulates subcellular trafficking of APP.[53] Reduced expression of *SORL1* leads to release of APP into endosomal pathways, where it is subjected to beta- and gamma-secretase cleavage, with subsequent production of Aβ. The SORL1 protein also belongs to a superfamily of low-density lipoprotein receptors (SorLA/LR11) which bind ApoE and are implicated in cholesterol metabolism and atherogenesis. There is evidence for reduced *SORL1* expression in the brains of patients with AD,[57] which was found to be associated with increased Aβ production.[58] In AD patients, *SORL1* variants associated with AD are also associated with whole-brain and hippocampal atrophy on MRI. [59] Heterogeneity still remains in *SORL1* alleles, however, and broad regions of *SORL1* still need to be examined for functional pathogenic variants.

## GAB2

*GAB2*, on chromosome 11q, was recently identified as a susceptibility gene for LOAD.[60] A genome-wide association study reported that a haplotype encompassing six polymorphisms of the *GAB2* gene is associated with a higher risk of developing AD,[60,61] especially in *ApoE ε4* allele carriers.[61] The hypofunctional *GAB2* haplotype is thought to be associated with a reduced GAB2-protective effect on neurones. GAB2 is a scaffolding protein involved in multiple signalling pathways, which is thought to protect cells from NFT formation and cell death.[62] Neuronal microarray studies provided evidence that GAB2 is biologically relevant to AD neuropathology by showing that LOAD cases had significantly greater neuronal *GAB2* expression in the posterior cingulate cortex and hippocampus than controls.[60] The relationship between *GAB2* polymorphisms and Aβ metabolism has not yet been established.

## PCDH11X

*PCDH11X* is a gene located on chromosome X encoding protocadherin 11. Protocadherin belongs to the cadherin family of cell surface receptor molecules. The cadherin proteins mediate cell–cell adhesion and have a role in cell signalling that is critical in the development of the central nervous system. Notably, some protocadherins are known to undergo presenilin-dependent processing.[63] A genome-wide association study identified a SNP on chromosome X which resides in a haplotype block that falls entirely within *PCDH11X* and strongly segregated with LOAD.[64] Female homozygotes showed a significantly increased risk for AD compared with female non-carriers, female heterozygotes and male hemizygotes.[64] Moreover, female heterozygotes were at increased risk over female non-carriers, and male hemizygotes were at higher risk than male non-carriers.[64] To obtain a perspective about the importance of *PCDHX11* to LOAD, it is useful to compare the risk for LOAD associated with *PCDHX11* with that for *ApoE*. The odds ratio for LOAD associated

with the homozygous *ApoE ε4* allele is 11.5, whereas for homozygous *PCDH11X* it is 1.75 (http://www.physorg.com/news150905504.html). These results await replication.

### KIBRA alleles

Recent genome-wide studies aimed at identifying memory-related gene variants have shown an association between the *KIBRA* gene on chromosome 5q and human memory performance.[65,66] KIBRA is a cytoplasmic protein that is highly expressed in the brain and is a binding partner of dendrin, a putative modulator of synaptic plasticity. A SNP within the ninth intron of *KIBRA* was shown to influence episodic memory.[65] There are two allelic variants of *KIBRA* (T and C), which result in three possible genotypes: *TT, CT* and *CC*. *KIBRA T* allele carriers (*CT* and *TT* genotypes) had better episodic memory performance than *KIBRA CC* carriers in young, middle-aged and elderly subjects.[65,66] Moreover, *KIBRA CC* carriers had a moderate but significantly increased risk of AD compared with *TT* and *CT* carriers.[67,68]

In functional MRI (fMRI) studies, *KIBRA CC* carriers showed greater activation of the hippocampus and frontal and parietal cortex compared with the *T* allele carriers during an episodic memory task, suggesting that these memory retrieval-related regions had to work harder to perform the task in the *T* allele non-carriers.[65,67] Moreover, ^{18}F-FDG PET studies showed that cognitively normal *KIBRA CC* carriers had significantly lower CMRglc than *KIBRA TT* and *CT* carriers in the posterior cingulate cortex.[67]

Although familial LOAD shows high heritability, which indicates genetic involvement, no well-replicated susceptibility genes have been identified to date, with the exception of *ApoE* and *SORL1*. Studies are mostly hindered by the fact that LOAD is a common complex disorder of old age, with multi-factorial causes, including genetic and environmental components. Such aetiological complexity makes identification of LOAD-related genes challenging, whereas an 'endophenotype approach' may afford some advantage.[69] Measuring phenotypic variation in pre-selected, homogeneous populations may expedite the search for specific genotypes.

## Family history of LOAD: Evidence for maternal transmission

### Prevalence and risk

Descriptively, two main variants of LOAD can be identified:

1. LOAD with a familial component (LOFAD), which includes:

   • Individuals with a parent, or both parents, affected with AD

   • Individuals with first-degree family members other than the parents affected with AD (ie siblings)

   • Individuals with second-degree family members affected with AD (ie aunts, uncles, grandparents)

   • Combinations of the above.

2. LOAD that appear to be sporadic in nature (LOSAD). These individuals are the first in their families to develop AD.

After advanced age, having a first-degree family history of LOAD is the most significant risk factor for developing AD among NL individuals.[70,71] First-degree relatives of affected probands have a four- to tenfold higher risk for developing AD than the general population, with some variability depending on which family members are affected.[72-74] Children of affected parents are at especially high risk of AD, as confirmed in multiethnic studies.[73]

Although having one parent with AD is *per se* a major risk factor for developing AD in the offspring, individuals with both parents affected appear to be at even greater risk for AD, compared with those with one affected parent and with the general population.[75,76] In general, individuals with LOFAD tend to develop dementia at younger ages than in LOSAD. [77] Moreover, the age at onset of AD was lower in children with both parents with AD (mean age of onset 57 years, range 48–66) compared with children with one parent with AD (mean age of onset 60 years, range 50–80), and with those with no parents affected (mean age of onset 72 years, range 48–88).[75]

Although there is mixed evidence for parent of origin gender effects in LOAD families,[78,79] epidemiological studies have shown that maternal transmission of AD may have a greater impact on the offspring's health than paternal transmission. AD affects more women than men, with a relative risk of 1.5–3.6 across different ethnic groups,[73] and maternal transmission is more frequent than paternal transmission of AD.[80] In AD patients with one affected parent, the ratio of mother-to-father affected is approximately 3:1 (Table 2). A review of the AD literature[70,77,78,80,81] and data from the authors' current studies show that approximately 20 per cent of all LOAD cases are maternally inherited. Importantly, having an AD-affected mother was found to be associated with poorer cognitive performance in late life[82] and with a lower and more predictable age at onset of dementia in the offspring, compared with having an AD-affected father.[77,80,83]

There are no published studies that have examined whether cognitive performance deteriorates at younger ages in individuals with both parents affected, compared with those with one parent with AD. As individuals with both parents with AD are relatively rare (estimated prevalence is 3–5 per cent of the total AD population)[75] their clinical profile has been poorly studied.

At present, the absolute risk to the offspring associated with either an affected mother or father is not known. There is a paucity of longitudinal studies in pre-symptomatic AD. It is not known whether the prevalence of cognitive decline from normal to AD is higher in children of AD mothers compared with children of AD fathers, or with different family history. The genetic and pathological mechanisms through which a parental, especially maternal, history of AD confers increased susceptibility to the offspring remain largely unknown. Genetically mediated risk for a large proportion of LOAD cases is evident from the familial aggregation of AD and is only partially explained by the risk conferred by *ApoE ε4* alleles. The *ApoE ε4* genotype is found in fewer than 40 per cent of LOFAD cases,[70] and not everyone with an *ApoE ε4* allele will develop AD. This indicates that other factors contribute to the aetiology and phenotypic expression of the disease. Thus far, these epidemiological and clinical findings have not been thoroughly characterised by the use of bio-markers, and LOFAD phenotypes have not been fully studied.

### Brain imaging studies of maternal history of AD

^{18}F-FDG PET imaging studies have provided evidence for phenotypic differences between NL individuals with a maternal history of AD and those with a paternal family history.[7,84] Examination of a group of over 50 50–80-year-old clinically normal and NL individuals showed that those subjects with an AD mother had reduced CMRglc compared with those with an AD father and with those with no parents affected (Figure 2).[7] CMRglc reductions in the children of AD mothers involved the brain regions typically affected in clinical AD patients — namely, the parieto-temporal, posterior cingulate/precuneus, medial temporal and prefrontal cortices. No CMRglc differences were found between children of AD fathers and children of parents with no dementia. Moreover, CMRglc reductions in children of AD mothers remained significant after accounting for other possible risk factors for AD, such as age, gender, education and *ApoE* genotype. Importantly, hypometabolism was found within

the group of maternal AD subjects irrespective of their *ApoE* status. *ApoE ε4* non-carriers with an AD mother showed CMRglc reductions compared with the *ApoE ε4* non-carriers with an AD father and those with no parents affected. These data show that CMRglc reductions in individuals with an AD mother occur independently of the subjects' *ApoE* genotype.[7]

Over a two-year follow-up interval, CMRglc reductions in NL subjects with an AD mother were observed to be progressive.[84] Longitudinally, subjects with an AD-affected mother showed progressive, bilateral CMRglc reductions in the posterior cingulate/precuneus, parieto-temporal and frontal cortices (Figure 3). By contrast, individuals with an AD-affected father and those with no parental history of AD showed longitudinal CMRglc reductions restricted to the frontal cortex, which is a typical effect of the ageing process. Within all these brain regions, CMRglc reductions over time were more severe in children of AD mothers compared with the other groups.[84]

This study included two subjects, one with an AD mother and the other with an AD father, whose AD parents were autopsied and given a postmortem diagnosis of AD. Examination of the individual ^{18}F-FDG PET scans of these subjects showed that, compared with controls, the 68-year-old NL son of an AD-affected father did not show hypometabolism in any brain regions, whereas the 58-year-old NL daughter of an AD-affected mother showed significant CMRglc reductions in AD-vulnerable regions (Figure 4).

Of relevance to the above results, ^{18}F-FDG PET studies in NL elderly individuals showed that CMRglc reductions in AD brain regions both predict and correlate with the decline from normal cognition to MCI and AD.[85,86] Reduced CMRglc at baseline accurately predicted future cognitive decline from normal to AD with 81 per cent accuracy, and from normal to MCI with 71 per cent accuracy.[86] Over the study interval, the rate of CMRglc reduction was four times higher in the progressors to AD, than in the non-progressors.[86]

The current observations suggest, and further longitudinal studies will be needed to confirm, that NL children of AD-affected mothers who have progressive CMRglc reductions in AD regions may be in the preclinical stages of AD. Clarification is also needed about whether an additive effect on regional hypometabolism occurs when both parents are AD affected. Finally, multi-modality imaging is warranted to assess the relationship between hypometabolism in children of AD mothers with Aβ and NFT pathology, or other biological markers of AD.

## Searching for genes involved in maternally inherited AD

Classical genetic studies are challenging to perform in LOAD cases because the parents are usually not alive or the children are too young to manifest the phenotype of the disease. The above brain imaging findings in children of AD mothers provide a unique opportunity for studying and uncovering new genetically mediated risk factors for LOAD. Although Mendelian inheritance is not evident in LOFAD, the fact that children of affected individuals have an increased risk of developing the disease suggests a genetic component. Moreover, the fact that only children of affected mothers show CMRglc reductions consistent with AD, suggests a maternally inherited predisposition to brain 'energetic' failure. The most likely genetic mechanisms to explain maternally inherited AD would appear to be (in alphabetical order):

- chromosome X-mediated transmission

- epigenetic imprinting

- mitochondrial DNA-mediated transmission

- sex-specific trinucleotide repeat expansions-mediated transmission,

## Chromosome X

Chromosome X-linked diseases are disorders that reflect the presence of defective genes on the X chromosome. The vast majority of X-linked diseases are characterised by recessive transmission with the following features: 1) males are more frequently affected than females because they are hemizygous and the gene defect is not balanced by a normal X chromosome; 2) females are rarely affected because they need to be homozygous for the defective gene to manifest the phenotype; 3) there is no male-to-male transmission; 4) transmission of the defective gene occurs from fathers to daughters, who become carriers; 5) males born to a carrier mother have a 50 per cent probability of inheriting the X chromosome carrying the defective gene. Classical examples of X-linked transmission are red–green colour blindness and haemophilia A.

The presence of X-linked inheritance could be a possible explanation for the higher prevalence of maternal transmission of AD. As described above, the 'X-linked hypothesis' for a LOAD gene was supported by a recent genome-wide association study, which identified a strong association between LOAD and a mutation located on the *PCDH11X* gene on chromosome X.[64] Female homozygotes were at significantly increased risk for AD compared with female non-carriers, female heterozygotes and male hemizygotes.[64] Moreover, female heterozygotes were at greater risk than female non-carriers, and male hemizygotes were at higher risk than male non-carriers.[64]

Although maternally inherited LOFAD and X-linked diseases may share some characteristics, several properties of recessive X-linked disorders do not apply to LOFAD. First, *PCDH11X* mutations were associated with higher risk in female homozygotes than male hemizygotes, which is contrary to what is usually found in X-linked recessive disorders.[64] Secondly, there is no male-to-male transmission in X-linked inheritance, whereas father-to-son transmission has been reported in AD.[79,80] Although limited by sample size, in the authors' PET studies, there was no evidence for gender effects in the offspring of AD mothers.[7] Males withanADmother did not show more severe hypometabolism when compared with females with AD mothers. These results need to be confirmed with larger data sets specifically to examine the interaction between family history and gender on brain metabolism and other variables.

## Genomic imprinting

Genomic imprinting is a genetic process by which certain genes are expressed in a parent-of-originspecific manner, which does not follow classical Mendelian inheritance.[87] While expression of the majority of genes derives from both inherited copies (alleles) of the gene, a small proportion (<1 per cent) of genes are imprinted, which means that gene expression occurs from only one allele. In the majority of cases, one of the parental alleles is completely silenced and gene expression is monoallelic. This silencing mechanism is known to involve epigenetic marking by allele-specific DNA methylation and/or histone modifications.[88] Differential epigenetic marking of the parental chromosomes results in differential reading by the transcriptional machinery and, as a consequence, gene expression is predominantly from one parental allele. For example, the gene encoding insulin-like growth factor 2 (*IGF2/Igf2*) is only expressed from the allele inherited from the father.

For a gene that is normally imprinted with paternal silencing, a mutation in the maternal copy of the gene will result in disease, while a mutation in the paternal copy will have no effect, and vice versa. According to the parental conflict hypothesis, paternal imprinting appears to be growth promoting, while maternal imprinting would be growth limiting.[89]

More specifically, the paternal genome maximises extraction of maternal resources for the benefit of the paternal offspring, at the expense of offspring from other embryos, possibly from different fathers. By contrast, the maternal genome limits nutrient provision to each individual embryo to distribute resources equally among her offspring, independent of the fathers. Irrespective of parental origin, the majority of imprinted genes in mammals have roles in the control of embryonic growth and development, including development of the placenta, and in postnatal development, with roles affecting suckling and metabolism.[87]

Imprinted genes are susceptibility targets for numerous human pathologies because their functional haploid state enables a single genomic or epigenomic change to dysregulate their function. Recent evidence has highlighted the role of genetic imprinting on brain function for PraderWilli and Angelman syndromes, as well as more common disorders like diabetes, obesity, breast cancer, autism, bipolar disorder, Tourette's syndrome, epilepsy and even AD.[87] Maternal imprinting may be a genetic mechanism responsible for the increased maternal inheritance in LOFAD cases. Some reports showed that the methylation process involved in imprinting is altered in AD patients, compared with controls.[90] A genome-wide screening of AD families reported a linkage between LOAD and a region close to the centromere of chromosome 10q only in families with an AD affected mother.[91] While these findings suggest imprinting,[91] there is no clear evidence for the existence of imprinted genes in AD families on chromosome 10 or on other chromosomes.

With respect to our $^{18}$F-FDG PET findings, hypometabolism in children of AD mothers suggests 'metabolic imprinting'. Metabolic imprinting refers to the epigenetic programming of metabolism during the prenatal and neonatal periods and may have long-term consequences for health.[87] For example, glucocorticoid exposure in late pregnancy and foetal under-nutrition have been linked to increased risk for cardiovascular disease, obesity, type two diabetes and hypertension.[87,92] In animal studies, most of the 80 known imprinted genes are expressed in the placenta and influence maternofoetal nutrient transfer during gestation and placental growth.[93] Maternal nutrition itself was shown to have a role in hormonal imprinting. The presence of harmful substances or the lack of important substrates in the mother's diet can induce adult-onset disease in the progeny.[92] Little is known about hormonal imprinting of the brain, however, and there are currently no studies that have examined imprinting as a source of metabolic dysregulation in AD.

Finally, there is evidence from animal models for X chromosome-linked imprinted genes that could influence sexually dimorphic neurobiology.[94] The X chromosome is enriched for genes affecting neurodevelopment. Investigations into imprinted genes on chromosome X may provide insights into why women and men apparently show differential vulnerability to AD.[94] As with chromosome X mutations, findings of gender effects on brain deficits would support a role for this mechanism in AD.

## Mitochondrial DNA

Mitochondrial disorders are entirely maternally inherited in humans and are characterised by variable phenotypic expression. Male and female progeny are equally likely to receive mutant maternal mitochondrial DNA (mtDNA). The same mtDNA mutation may affect different organs in different individuals, and may lead to minor or severe defects. The prominent role of mitochondrial function in regulating molecular processes involved in glucose metabolism suggests the possibility that mtDNA mutations, with resulting mitochondrial dysfunction and oxidative damage, may be involved in the pathophysiology of AD. Mitochondrial dysfunction may also be responsible for alterations in glucose metabolism in AD brain tissue[95] and the selective metabolic impairment in children of AD mothers. The fact that mtDNA is exclusively maternally inherited in humans lends support to this hypothesis.

Human mtDNA is a 16,569-kilobase circular, double-stranded molecule, which contains 37 genes: two rRNA genes, 22 tRNA genes and 13 structural genes that encode electron transport chain (ETC) subunits and the mitochondrial ATP synthase. While most ETC proteins (ie complex II, coenzyme Q and cytochrome c) are encoded by nuclear DNA, mtDNA encodes the catalytic components of complexes I, III, IV and V, all of which are essential for maintaining physiological oxidative phosphorylation (OXPHOS). OXPHOS is the process that accounts for the high ATP yield by the cells, and is essential to the maintenance of cellular homeostasis and function.

The brain has high energy requirements, contains a large number of mitochondria and is therefore highly susceptible to reductions in aerobic metabolism. Deficient energy metabolism may change the overall oxidative microenvironment for neurones during the pathogenesis of AD, rendering synapses more vulnerable to Aβ and tau pathology.

Mutations of mtDNA lead to a number of illnesses caused by inadequate energy supply that mostly present as neuromuscular diseases.[96] These range from exercise intolerance to diseases with severe body-wide impact, such as the mitochondrial encephalopathy, lactic acidosis and stroke syndrome (MELAS — a rare form of dementia associated with seizures); headaches; muscle disease and stroke-induced paralysis; and Kearns–Sayre syndrome (KSS), which causes a person to lose full function of their heart, eye and muscle movements. In addition to mitochondrial myopathies, other mtDNA diseases include diabetes mellitus and deafness (DAD), Leber's hereditary optic neuropathy (LHON) and Leigh syndrome (see below).

For more than 15 years, evidence has accumulated that AD is associated with mitochondrial dysfunction, oxidative stress and increased reactive oxygen species (ROS) production. At postmortem, extensive oxidative stress is found in AD brains, in which basically all cellular macromolecules (protein, DNA, lipids) are found in an oxidised form.[97-99] A specific mitochondrial defect demonstrated in AD is reduced cytochrome oxidase (COX) activity in brain regions showing neuronal loss.[100-104] COX (ETC complex IV) is the mitochondrial enzyme responsible for the activation of oxygen for aerobic energy metabolism and is critically tied to ATP production in mitochondria.[105,106] COX is localised primarily in mitochondria near excitatory synapses in neuronal dendrites, and its activity is tightly linked to the regulation of CMRglc in the synapses.[105] Preferentially reduced COX activity in AD was shown in several *in vivo* studies of blood platelets[107-112] and fibroblasts.[100,111,113] Platelet mitochondria COX activity was also significantly reduced in MCI patients compared with controls.[112] Overall, these studies provide evidence for peripheral abnormalities in COX activity and increased oxidative stress in such cells as blood platelets and fibroblasts, which are non-degenerating tissues and should not be affected by brain pathology. This suggests that COX reductions may not be simply a secondary or epiphenomenal consequence of neurodegeneration, but may instead represent a systemic perturbation in AD.

Nonetheless, mtDNA studies in AD have provided non-conclusive, and often conflicting, results. Studies that investigated the role of mtDNA mutations in AD have used three main approaches: cytoplasmic hybrid (cybrid) analyses, case-control mutation identification studies and mitochondrial haplogroup association studies. Studies of cybrid cells provide direct evidence for mtDNA involvement in the metabolic abnormalities characteristic of AD (Figure 5). Cybrids are obtained by mixing mtDNA from affected patients' platelets with cell lines depleted of their own endogenous mtDNA, resulting in cell lines containing mtDNA from the patient.[115] These cell lines expand under standard culture conditions, and their biochemical assessment allows investigators to evaluate parameters directly or indirectly referable to mitochondria and presumably the mtDNA they carry.[116] Cybrid data

in AD show that mtDNA at least partly accounts for impaired metabolism and increased oxidative stress in AD, as reflected in increased ROS production. Defects in mitochondrial respiratory enzymes, particularly affecting COX activity, increase changes in calcium homeostasis, decrease ATP production, enhance Aβ toxicity and vastly increase the percentage of morphologically abnormal mitochondria.[117-120]

In addition to cybrid studies, several case-control studies using mutation identification and mitochondrial haplogroup association studies suggest that maternally inherited mutations of mtDNA may play a pathogenic role in AD (Table 3). Despite the observation of mtDNA mutations in AD versus controls, and of associations observed between specific haplotypes and an increased risk for AD, however, many of these exploratory findings were not confirmed by subsequent studies.[95] Therefore, the role of mitochondrial genome changes in the pathogenesis of ageing and AD needs further clarification, and it is possible that the maternally inherited metabolic endophenotype may be helpful for such investigations.

### Sex–specific trinucleotide repeat expansions

Trinucleotide repeat disorders (TRD) are a class of molecular diseases characterised by the presence of unstable and abnormal expansions of DNA triplets (trinucleotides). Mutations present as a subset of unstable repeats that occur throughout the genomic sequence, resulting in chromosomal instability. Generally, the larger the expansions, the more likely they are to cause disease or increase the severity of disease. This property results in the phenomenon of genetic anticipation, as is evident in TRDs, in which there is a tendency for age of onset to decrease and severity of symptoms to increase through successive generations of an affected family, due to the expansion of these repeats.[130] Large increases or expansions in the number of trinucleotide tandem repeats are involved in a number of inherited neurodegenerative conditions, which appear to be specific to the gender of the transmitting parent. For example, in Huntington's disease there is an increased number of CAG repeats, and this condition is preferentially paternally inherited.[131] Some neurological TRDs show a preferential maternal transmission, such as fragile X syndrome,[132] Friedreich ataxia,[133] spinocerebellar ataxia type 8[63] and myotonic dystrophy.[134] Trinucleotide expansions may also be involved in some cases of frontotemporal dementia, although results are not conclusive.[135,136] There is currently no evidence for trinucleotide repeat expansions in AD.

## Maternal transmission in neurological disorders other than AD

A wide spectrum of diseases has been associated with preferential maternal transmission resulting from various genetic mechanisms. Parkinson's disease has more common features with AD than the other disorders, and is therefore presented separately and in more detail.

### Parkinson's disease

Parkinsonian syndromes are movement disorders that can be divided into idiopathic Parkinson's disease (PD), multiple system atrophy (MSA) and parkinsonian syndromes (PDS) secondary to other conditions or exogenous agents. While MSA and PDS are purely movement disorders, it is not uncommon for PD patients to develop dementia.[137] PD is a neurodegenerative disease that typically impairs motor skills, speech and other cognitive functions, and is characterised by muscle rigidity, tremor, bradykinesia (ie slowing of physical movement) and akinesia (ie loss of physical movement) in severe cases.[138] The primary symptoms are the result of decreased stimulation of the motor cortex due to degeneration of dopaminergic neurones in the substantia nigra.

As in AD, epidemiological data indicate that the risk of developing PD is greater for a person whose mother was affected by the disease than for the off-spring of an affected

father.[139,140] Moreover, only maternal transmission of PD was found to affect the age at onset in affected families.[141]

While there is no evidence for chromosome X mutations or imprinting in PD, it is now widely accepted that inherited or somatic mtDNA variations contribute to the aetiology of PD (Table 4). Mitochondrial damage in PD results in ETC complex I deficits (instead of the ETC complex IV deficits typically observed in AD).[95] PD was one of the first identified neurodegenerative mitochondriopathies. In the early 1980s, a toxin-induced subacute parkinsonism syndrome reminiscent of idiopathic PD was described.[148] The responsible toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), was next shown to inhibit ETC complex I. MPTP administration to laboratory animals has been found to destroy the substantia nigra and even induced Lewy body formation in aged chimpanzees.[148] Subsequent research revealed that other complex I inhibitors induce a parkinsonism phenotype, loss of dopaminergic nigral neurones and histological changes similar to those seen in human PD.[149] Complex I enzymatic lesions, but not other ETC enzymes, are found in PD patients in both the substantia nigra and muscle,[150] which may be due to mtDNA mutations.[151-153]

The cybrid technique has provided an effective strategy for probing the role of mtDNA in PD as well as AD subjects.[154] To summarise the results of PD cybrid studies, transferring PD platelet mitochondria to mtDNA-depleted human cells produced cell lines with reduced complex I activity, elevated peroxide levels, increased antioxidant enzyme activities, altered calcium and signalling pathway homeostasis and cytoplasmic protein aggregations that contain α synuclein.[155] Of great relevance to the imaging findings in children of AD mothers, a cybrid study in PD examined ETC activity of multiple members over three generations affected with PD through exclusively maternal lines and compared them with those of paternally descended family members.[156] Compared with the cybrid lines containing mtDNA from paternal descendants, cybrid lines containing mtDNA from maternal descendants had lower complex I activity, increased ROS production and more abnormal mitochondrial morphologic features.[156] These findings were present in cybrid lines containing mtDNA from maternal descendants affected with PD as well as in asymptomatic young maternal descendants.[156] These data indicate that mtDNA mutations may be a primary genetic deficit in maternally inherited PD. There are currently no published imaging studies that have compared symptomatic or pre-symptomatic children of PD mothers with children of PD fathers.

**Maternal transmission of other neurological disorders**—Several neurological disorders show preferential maternal inheritance (Table 5). Overall, these maternally inherited disorders are characterised by phenotypic manifestation mainly in infancy or early adulthood. Disorders due to mtDNA mutations are more frequent and typically present as multi-systemic diseases. None of these disorders resemble the clinical phenotype of AD; however, some reports have suggested a link between AD and maternally inherited neurological disorders. For example, mitochondrial haplogroup J has been associated with increased risk of AD, MELAS and LHON.[168]

## Conclusions, implications and future challenges

Clinical and epidemiological studies show that maternally inherited AD may account for over 20 per cent of all LOAD cases, and children of AD mothers are at higher risk for developing AD than children of AD fathers. Brain ^{18}F-FDG PET studies have shown that children of AD mothers are at risk of developing brain hypometabolism early in life, which may partially explain the increased predisposition. Genetic mechanisms involved with maternally inherited metabolic deficits in AD are under investigation.

Metabolic deficits in normal individuals with a maternal history of AD represent a unique opportunity for the initiation of AD therapies and general preventive methods years — and possibly decades — prior to the onset of the clinical disease, presumably well before significant neuronal loss occurs. CMRglc reductions in asymptomatic children of AD mothers can ideally be used as a surrogate marker of AD progression in clinical trials to test the potential of preventive treatments for AD.[51] Moreover, they could be used as a biomarker of AD in quantitative trait genetic analysis, instead of standard case-control studies, to examine the genes involved in maternal transmission in AD. The combination of imaging and custom-tailored genetics may help to clarify whether changes in the nuclear or mitochondrial genome and transcriptome account for pathogenic ageing and AD.

It is important to underline that the genes involved in maternally inherited AD do not follow an autosomal dominant pattern of transmission, and penetrance does not appear to be high, as many children of mothers with AD do not develop the disease. Although the presence of a maternal history of AD indicates that children may be at higher risk, it does not imply that the children are carriers of the hypothesised mutated gene or allelic variant. The maternal link may not be the only cause of AD in the children, who may develop sporadic AD, or AD linked to non-maternal genetic risk factors for LOAD, however. All of these non-maternally inherited genetic or sporadic causes of AD may also lead individuals to develop a metabolic pattern comparable with that described in our studies. Moreover, the AD mothers may have sporadic LOAD, which would probably not be inherited by the children. In this case, multi-generational studies may help to identify individuals with a definite history of maternally inherited AD spanning two or more generations.

Finally, evidence for early metabolic deficits in the children of AD mothers suggests that this form of LOFAD may be both a neurodevelopmental and a neurodegenerative disorder. Several studies have hypothesised a direct relationship between early development and late-life neurodegeneration based on similarities between APP and the Notch protein, which is critically involved in central and peripheral nervous system development and, like APP, is cleaved by presenilins.[169,170] APP was shown to be a ligand for death receptor 6 (DR6), which triggers neurodegeneration during embryonal development.[171] In particular, in NGF knockout mice, trophic deprivation led to the cleavage of surface APP by beta-secretase, with generation of an N-APP fragment which bound DR6, triggering caspase activation and degeneration of both neuronal cell bodies (via caspase 3) and axons (via caspase 6).[171] Therefore, the pathological process in AD may begin as early as at birth, as a result of lack of trophic support and nutrients to the embryo. This observation suggests a role for metabolic imprinting in neurodegeneration in AD, which can only be maternally inherited.

In conclusion, integration of information from genetic, transcriptomic and proteomic studies, and from *in vivo* biomarkers, will greatly advance our understanding of the causes of AD, improve our ability to establish an early diagnosis, help to define disease subgroups and, ultimately, help to develop preventive treatments based on individuals' own pathophysiology.

## Acknowledgments

## References

1. Kukull WA, Higdon R, Bowen JD, McCormick WC, et al. Dementia and Alzheimer disease incidence: A prospective cohort study. Arch. Neurol 2002;59:1737–1746. [PubMed: 12433261]

2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, et al. State-specific projections through 2025 of Alzheimer disease prevalence. Neurology 2004;62:1645. [PubMed: 15136705]

3. Fratiglioni L, Grut M, Forsell Y, Viitanen M, et al. Prevalence of Alzheimer's disease and other dementias in an elderly urban population: Relationship with age sex, and education. Neurology 1991;41:1886–1892. [PubMed: 1745343]

4. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 1998;88:1337–1342. [PubMed: 9736873]

5. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS–ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–944. [PubMed: 6610841]

6. Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759–1766. [PubMed: 12480441]

7. Mosconi L, Brys M, Switalski R, Mistur R, et al. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc. Natl. Acad. Sci. USA 2007;104:19067–19072. [PubMed: 18003925]

8. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008;7:161–172. [PubMed: 18207114]

9. Scheltens P, Fox N, Barkhof F, De Carli C. Structural magnetic resonance imaging in the practical assessment of dementia: Beyond exclusion. Lancet Neurol 2002;1:13–21. [PubMed: 12849541]

10. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005;32:486–510. [PubMed: 15747152]

11. Silverman DHS, Gambhir SS, Huang HW, Schwimmer J, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. J. Nucl. Med 2002;43:253–266. [PubMed: 11850493]

12. Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. Br. J. Radiol 2007;2:160–167.

13. Mosconi L, Pupi A, de Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann. NY Acad. Sci 2009;1147:180–195. [PubMed: 19076441]

14. Klunk WE, Engler H, Nordberg A, Yamming W, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol 2004;55:306–319. [PubMed: 14991808]

15. Kemppainen N, Aalto S, Wilson I, Nagren K, et al. Voxel–based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575–1580. [PubMed: 16971697]

16. Pike KE, Savage G, Villemagne VL, Ng S, et al. Beta amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 2007;130:2837–2844. [PubMed: 17928318]

17. Mintun MAM, LaRossa GN, Sheline YIM, Dence CSM, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006;67:446–452. [PubMed: 16894106]

18. Fagan AM, Mintun MA, Mach RH, Lee S, et al. Inverse relation between *in vivo* amyloid imaging load and cerebrospinal fluid. Ann. Neurol 2006;59:512–519. [PubMed: 16372280]

19. Tanzi RE, Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 2001;32:181–184. [PubMed: 11683989]

20. St George–Hyslop P. Molecular genetics of Alzheimer's disease. Biol. Psychiatry 2000;47:183–199. [PubMed: 10682216]

21. Mirra SS, Heyman A, McKeel D, Sumi SM, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479–486. [PubMed: 2011243]

22. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol 1999;45:358–368. [PubMed: 10072051]

23. Selkoe DJ. Alzheimer's disease: Genotypes, phenotype, and treatments. Science 1997;275:630–631. [PubMed: 9019820]

24. Lue LF, Kuo YM, Roher AE, Brachova L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol 1999;155:853–862. [PubMed: 10487842]

25. Yankner BA, Davies LR, Fisher S, Villa-Komaroff L, et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 1989;245:417–420. [PubMed: 2474201]

26. Yankner BA, Duffy L, Kirschner D. Neurotrophic and neurotoxic effects of amyloid beta protein: Reversal by tachykinin neuropeptides. Science 1990;250:279–282. [PubMed: 2218531]

27. Geula C, Wu CK, Saroff D, Lorenzo A, et al. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat. Med 1998;4:827–831. [PubMed: 9662375]

28. Behl C, Davis J, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid [beta]protein toxicity. Cell 1994;77:817–827. [PubMed: 8004671]

29. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001;32:177–180. [PubMed: 11683988]

30. Kennedy AM, Frackowiak RSJ, Newman SK, Bloomfield PM, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett 1995;186:17–20. [PubMed: 7783942]

31. Mosconi L, Sorbi S, de Leon MJ, Nacmias B, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med 2006;47:1778–1786. [PubMed: 17079810]

32. Klunk WE, Price JC, Mathis CA, Tsopelas ND, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci 2007;27:6174–6184. [PubMed: 17553989]

33. Koivunen J, Verkkoniemi S, Aalto S, Paetau A, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008;131:1845–1853. [PubMed: 18583368]

34. Remes AM, Laru L, Tuominen H, Aalto S, et al. Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch. Neurol 2008;65:540–544. [PubMed: 18413480]

35. Di Fede G, Catania M, Morbin M, Rossi G, et al. A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009;323:1473–1477. [PubMed: 19286555]

36. Tomiyama T, Nagata T, Shimada H, Teraoka R, et al. A new amyloid B variant favoring oligomerization in Alzheimer's-type dementia. Ann. Neurol 2008;63:377–387. [PubMed: 18300294]

37. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, et al. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 2006;63:168–174. [PubMed: 16461860]

38. Gatz M, Pedersen NL, Berg S, Johansson B, et al. Heritability for Alzheimer's disease: The study of dementia in Swedish twins. J. Gerontol. A Biol. Sci. Med. Sci 1997;52:117–125.

39. Raiha I, Kaprio J, Koskenvuo M, Johansson B, et al. Alzheimer's disease in Finnish twins. Lancet 1996;347:573–578. [PubMed: 8596319]

40. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, et al. Apolipoprotein E: High-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993;90:1977–1981. [PubMed: 8446617]

41. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset alzheimer disease. Proc. Natl. Acad. Sci. USA 1993;90:9649–9653. [PubMed: 8415756]

42. Holtzman DM, Bales KR, Tenkova T, Fagan AM, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000;97:2892–2897. [PubMed: 10694577]

43. Holtzman DM. Role of apoE/A interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J. Mol. Neurosci 2001;17:147–155. [PubMed: 11816788]

44. DeMattos RB. Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci 2004;23:255–262. [PubMed: 15181254]

45. Bennet DA, Schneider JA, Wilson RS, Bienias JL, et al. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J. Neurol. Neurosurg. Psych 2005;76:1194–1199.

46. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: Possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J. Neurochem 2003;84:1215–1236. [PubMed: 12614323]

47. Reiman EM, Uecker A, Caselli RJ, Lewis S, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann. Neurol 1998;44:288–291. [PubMed: 9708558]

48. Geroldi C, Pihlajamaki M, Laakso MP, DeCarli C, et al. APOE–epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999;53:1825–1832. [PubMed: 10563634]

49. Small GW, Mazziotta JC, Collins MT, Baxter LR, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995;273:942–947. [PubMed: 7884953]

50. Small GW, Ercoli LM, Silverman DHS, Huang SC, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000;97:6037–6042. [PubMed: 10811879]

51. Reiman EM, Caselli RJ, Chen K, Alexander GE, et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001;98:3334–3339. [PubMed: 11248079]

52. Reiman EM, Chen K, Alexander GE, Caselli RJ, et al. Functional brain abnormalities in young adults at genetic risk for late-onset alzheimer's dementia. Proc. Natl. Acad. Sci. USA 2004;101:284–289. [PubMed: 14688411]

53. Rogaeva E, Meng Y, Lee JH, Gu Y, et al. The neuronal sortilin–related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet 2007;39:168–177. [PubMed: 17220890]

54. Lee JH, Cheng R, Schupf N, Manly J, et al. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch. Neurol 2007;64:501–506. [PubMed: 17420311]

55. Lee JH, Shibata N, Cheng R, Mayeux R. Possible association between SORL1 and Alzheimer disease? Dement. Geriatr. Cogn. Disord 2008;26:482. [PubMed: 18984959]

56. Meng Y, Lee JH, Cheng R, Mayeux R. Association between SORL1 and Alzheimer disease in a genome-wide study. Neuroreport 2007;18:1761–1764. [PubMed: 18090307]

57. Dodson SE, Gearing M, Lippa CF, Montine TJ, et al. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J. Neuropathol. Exp. Neurol 2006;65:866–872. [PubMed: 16957580]

58. Kolsch H, Jessen F, Wiltfang J, Lewczuk P, et al. Influence of SORL1 gene variants: Association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci. Lett 2008;440:68–71. [PubMed: 18541377]

59. Cuenco KT, Lunetta KL, Baldwin CT, McKee AC, et al. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch. Neurol 2008;65:1640–1648. [PubMed: 19064752]

60. Reiman EM, Webster JA, Myers AJ, Hardy J, et al. *GAB2* alleles modify Alzheimer's risk in *APOE* e4 carriers. Neuron 2007;54:713–720. [PubMed: 17553421]

61. Sleegers K, Bettens K, Brouwers N, Engelborghs S, et al. Common variation in GRB-associated binding protein 2 (GAB2) and increased risk for Alzheimer dementia. Hum. Mutat 2008;29:338–344.

62. Gu H, Saito K, Klaman LD, Fleming T, et al. Essential role for Gab2 in the allergic response. Nature 2001;412:186–190. [PubMed: 11449275]

63. Haas IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. J. Biol. Chem 2005;280:9313–9319. [PubMed: 15611067]

64. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset alzheimer's disease. Nat. Genet 2009;41:192–198. [PubMed: 19136949]

65. Papassotiropoulos A, Stephan DA, Huentelman MJ, Hoerndli FJ, et al. Common KIBRA alleles are associated with human memory performance. Science 2006;314:475–478. [PubMed: 17053149]

66. Almeida OP, Schwab SG, Lautenschlager NT, Morar B, et al. KIBRA genetic polymorphism influences episodic memory in later life, but does not increase the risk of mild cognitive impairment. J. Cell. Mol. Med 2008;12:1672–1676. [PubMed: 18194457]

67. Corneveaux JJ, Liang WS, Reiman EM, et al. Evidence for an association between KIBRA and late-onset alzheimer's disease. Neurobiol. Aging. 2008 doi:10.1016/jneurobiolaging2008.07. [Epub ahead of print].

68. Rodriguez–Rodriguez E, Infanti J, Llorca J, Mateo I, et al. Age-dependent association of KIBRA genetic variation and Alzheimer's disease risk. Neurobiol. Aging 2009;30:322–324. [PubMed: 17707552]

69. Mayeux R, Hyslop PS. Alzheimer's disease: Advances in trafficking. Lancet Neurol 2008;7:2–3. [PubMed: 18093545]

70. Farrer LA, Cupples LA, Haines JL, Hyman B, et al. Effects of age, sex, and ethnicity on the association between apolipo-protein E genotype and Alzheimer disease. JAMA 1997;278:1349–1356. [PubMed: 9343467]

71. Silverman JM, Raiford K, Edland S, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part VI. Family history assessment: A multicenter study of first degree relatives of Alzheimer's disease probands and nondemented spouse controls. Neurology 1994;44:1253–1259. [PubMed: 8035925]

72. Cupples LA, Farrer LA, Sadovnik AD, Relkin N, et al. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: The REVEAL study. Genet. Med 2004;6:192–196. [PubMed: 15266206]

73. Green RC, Cupples LA, Go R, Benke KS, et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002;287:329–336. [PubMed: 11790212]

74. Silverman JM, Ciresi G, Smith CJ, Marin DB, et al. Variability of familial risk of Alzheimer disease across the late life span. Arch. Gen. Psychiat 2005;62:565–573. [PubMed: 15867110]

75. Jayadev S, Steinbart EJ, Chi YY, Kukull WA, et al. Conjugal Alzheimer disease. Arch. Neurol 2008;65:373–378. [PubMed: 18332250]

76. Bird TD, Nemens EJ, Kukull WA. Conjugal Alzheimer's disease: Is there an increased risk in offspring? Ann. Neurol 1993;34:396–399. [PubMed: 8363356]

77. Duara R, Lopez-Alberola RF, Barker WW, Loewenstein DA, et al. A comparison of familial and sporadic Alzheimer's disease. Neurology 1993;43:1377–1384. [PubMed: 8327141]

78. Edland SD, Silverman JM, Peskind ER, Tsuang D, et al. Increased risk of dementia in mothers of Alzheimer's disease cases: Evidence for maternal inheritance. Neurology 1996;47:254–256. [PubMed: 8710088]

79. Ehrenkrantz D, Silverman JM, Smith CJ, Tsuang D, et al. Genetic epidemiological study of maternal and paternal transmission of Alzheimer's disease. Am. J. Med. Genet 1999;88:378–382. [PubMed: 10402505]

80. Gomez–Tortosa E, Barquero MS, Baron M, Saint HJ, et al. Variability of age at onset in siblings with familial Alzheimer disease. Arch. Neurol 2007;64:1743–1748. [PubMed: 18071037]

81. Heyman A, Wilkinson WE, Hurwitz BJ, Schmechel D, et al. Alzheimer's disease: Genetic aspects and associated clinical disorders. Ann. Neurol 1983;14:507–515. [PubMed: 6228188]

82. Seshadri S, Wolf PA, Beiser A, Au R, et al. Lifetime risk of dementia and Alzheimer's disease: Estimates from the Framingham study. Neurology 1996;46:411–412.

83. Duara R, Barker WW, Lopez-Alberola R, Loewenstein DA, et al. Alzheimer's disease: Interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity, and age of onset. Neurology 1996;46:1575–1579. [PubMed: 8649551]

84. Mosconi L, Mistur R, Glodzik L, Brys M, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer's. Neurology 2009;72:513–520. [PubMed: 19005175]

85. de Leon MJ, Convit A, Wolf OT, Tarshish CY, et al. Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/ PET). Proc. Natl. Acad. Sci. USA 2001;98:10966–10971. [PubMed: 11526211]

86. Mosconi L, De Santi S, Li J, Tsui WH, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol. Aging 2008;29:676–692. [PubMed: 17222480]

87. Constancia M, Kelsey G, Relk W. Resourceful imprinting. Nature 2004;432:53–57. [PubMed: 15525980]

88. Gold JD, Pedersen RA. Mechanisms of genomic imprinting in mammals. Curr. Top. Dev. Biol 1994;29:227–280. [PubMed: 7828439]

89. Moore T, Haig D. Genomic imprinting in mammalian development: A parental tug-of-war. Trends Genet 1991;7:45–49. [PubMed: 2035190]

90. Payao SL, Smith MD, Bertolucci PH. Differential chromosome sensitivity to 5-azacytidine in Alzheimer's disease. Gerontology 1998;44:267–271. [PubMed: 9693257]

91. Bassett SS, Avramopoulos D, Fallin D. Evidence for parent of origin effect in late-onset alzheimer disease. Am. J. Med. Genet 2002;114:679–686. [PubMed: 12210287]

92. Csaba G. Hormonal imprinting: Phylogeny, ontogeny, diseases and possible role in present-day human evolution. Cell Biochem. Funct 2008;26:1–10. [PubMed: 17437316]

93. Wilkinson LS, Davies W, Isles AR. Genomic imprinting effects on brain development and function. Nat. Rev. Neurosci 2007;8:832–843. [PubMed: 17925812]

94. Davies W, Isles A, Smith R, Karunadasa D, et al. Xlr3b is a new imprinted candidate for X-linked parent-of-origin effects on cognitive function in mice. Nat. Genet 2005;37:625–629. [PubMed: 15908950]

95. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787–795. [PubMed: 17051205]

96. Schapira AH. Mitochondrial disease. Lancet 2006;368:70–82. [PubMed: 16815381]

97. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995;18:172–176. [PubMed: 7778188]

98. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol 1994;36:747–750. [PubMed: 7979220]

99. Subbarao KV, Richardson JS, Ang LC. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem 1990;55:342–345. [PubMed: 2355227]

100. Swerdlow RH. Treating neuro degeneration by modifying mitochondria: Potential solutions to a "complex" problem. Antiox. Redox Signal 2007;9:1591–1604.

101. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J .Neurochem 1994;63:2179–2184. [PubMed: 7964738]

102. Hirai K, Aliev G, Nunomura A, Fujioka H, et al. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci 2001;21:3017–3023. [PubMed: 11312286]

103. Valla J, Berndt JD, Gonzales-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: Superficial laminar cytochrome oxidase associated with disease duration. J. Neurosci 2001;21:4923–4930. [PubMed: 11425920]

104. Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: Selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J. Neuropathol. Exp. Neurol 1994;53:508–512. [PubMed: 8083692]

105. Wong-Riley MTT. Cytochrome oxidase: An endogenous metabolic marker for neuronal activity. Trends Neurosci 1989;12:94–101. [PubMed: 2469224]

106. Hevner RF, Wong-Riley MT. Neuronal expression of nuclear and mitochondrial genes for cytochrome oxidase (CO) subunits analyzed by in situ hybridization: Comparison with CO activity and protein. J. Neurosci 1991;11:1942–1958. [PubMed: 1648602]

107. Parker WD Jr, Filley CM, Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 1990;40:1302–1303. [PubMed: 2166249]

108. Parker WD Jr, Mahr NJ, Filley CM, Parks JK, et al. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 1994;44:1086–1090. [PubMed: 8208406]

109. Chandrasekaran K, Hatanpää K, Rapoport SI, Brady DR. Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease. Brain Res. Mol. Brain Res 1997;44:99–104. [PubMed: 9030703]

110. Bosetti F, Brizzi F, Barogi S, Mancuso M, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging 2002;23:371–376. [PubMed: 11959398]

111. Cardoso SM, Proenca MT, Santos S, de Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol. Aging 2004;25:105–110. [PubMed: 14675736]

112. Valla J, Schneider L, Niedzielko T, Coon KD, et al. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 2006;6:323–330. [PubMed: 17123871]

113. Curti D, Rognoni F, Gasparini L, Cattaneo A, et al. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neurosci. Lett 1997;236:13–16. [PubMed: 9404940]

114. Kish SJ, Bergeron C, Rajput AH, Dozic S, et al. Brain cytochrome oxidase in Alzheimer's disease. J. Neurochem 1992;59:776–779. [PubMed: 1321237]

115. Lucas JJ, Kates JR. The construction of viable nuclearcytoplasmic hybrid cells by nuclear transplantation. Cell 1976;7:397–405. [PubMed: 181145]

116. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med. Hypotheses 2004;63:8–20. [PubMed: 15193340]

117. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, et al. Cybrids in Alzheimer's disease: A cellular model of the disease? Neurology 1997;49:918–925. [PubMed: 9339668]

118. Khan SM, Cassarino DS, Abramova NN, Keeney PM, et al. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann. Neurol 2000;48:148–155. [PubMed: 10939564]

119. Trimmer PA, Swerdlow RH, Parks JK, Keeney PM, et al. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp. Neurol 2000;162:37–50. [PubMed: 10716887]

120. Cardoso SM, Santana I, Swerdlow RH, Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J. Neurochem 2004;89:1417–1426. [PubMed: 15189344]

121. Coskun PE, Beal MF, Wallace DC. Alzheimer's brains harbor somatic mtDNA controlregion mutations that suppress mitochondrial transcription and replication. Proc. Natl. Acad. Sci. USA 2004;101:10726–10731. [PubMed: 15247418]

122. Chinnery PF, Taylor GA, Howell N, Brown DT, et al. Point mutations of the mtDNA control region in normal and neurodegenerative human brains. Am. J. Hum. Genet 2001;68:529–532. [PubMed: 11133363]

123. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, et al. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 1994;23:471–476. [PubMed: 7835898]

124. Egensperger R, Kosel S, Schnopp NM, Mehraein P, et al. Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. Neuropathol. Appl. Neurobiol 1997;23:315–321. [PubMed: 9292870]

125. Shoffner JM, Brown MD, Torroni A, Lott MT, et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 1993;17:171–184. [PubMed: 8104867]

126. Wragg MA, Talbot CJ, Morris JC, Lendon CL, et al. No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. Neurosci. Lett 1995;201:107–110. [PubMed: 8848229]

127. Carrieri G, Bonafe M, De Luca M, Rose G, et al. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum. Genet 2001;108:194–198. [PubMed: 11354629]

128. van der Walt JM, Dementieva YA, Martin ER, Scott WK, et al. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci. Lett 2004;365:28–32. [PubMed: 15234467]

129. Chagnon P, Gee M, Filion M, Robitaille Y, et al. Phylogenetic analysis of the mitochondrial genome indicates significant differences betweenpatients withAlzheimer disease and controls in a French-Canadian founder population. Am. J. Med.Genet 1999;85:20–30. [PubMed: 10377009]

130. Brouwer JR, Willemsen R, Oostra BA. Microsatellite repeat instability and neurological disease. Bioessays 2009;31:71–83. [PubMed: 19154005]

131. Kehoe JP, Krawczak M, Harper PS, Owen MJ, et al. Age of onset in Huntington disease: Sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J. Med. Genet 1999;36:108–111. [PubMed: 10051007]

132. Mandel JL, Biancalana V. Fragile X mental retardation syndrome: From pathogenesis to diagnostic issue. Growth Horm. IGF Res 2004;14(Suppl. 1):158–165.

133. La Pean A, Jeffries N, Grow C, Ravina B, et al. Predictors of progression in patients with Friedreich ataxia. Mov. Disord 2008;23:2026–2032. [PubMed: 18759347]

134. Botta A, Rinaldi F, Catalli C, Vergani L, et al. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients. J.Med. Genet 2009;45:639–646. [PubMed: 18611984]

135. Ashworth A, Lloyd S, Brown J, Gydesen S, et al. Molecular genetic characterisation of frontotemporal dementia on chromosome 3. Dement. Geriatr. Cogn. Disord 1999;10:93–101. [PubMed: 10436350]

136. Mackenzie IR, Butland SL, Devon RS, Dwosh E, et al. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. BMC Neurol 2006;6:32–38. [PubMed: 16945149]

137. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004;363:1783–1793. [PubMed: 15172778]

138. Wider C, Wszolek ZK. Movement disorders: Insights into mechanisms and hopes for treatment. Lancet Neurol 2009;8:8–10. [PubMed: 19081502]

139. Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 2008;1792:651–663. [PubMed: 19059336]

140. Swerdlow RH, Parker WD, Currie LJ, Bennett JP, et al. Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkinsonism Relat. Disord 2001;7:129–133. [PubMed: 11248594]

141. Wooten GF, Currie LJ, Bennet JP, Harrison MB, et al. Maternal inheritance in Parkinson's disease. Ann. Neurol 1997;41:265–268. [PubMed: 9029076]

142. van der Walt JM, Nicodemus KK, Martin ER, Scott WK, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet 2003;72:804–811. [PubMed: 12618962]

143. Pyle A, Foltynie T, Tiangyou W, Lambert C, et al. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann. Neurol 2005;57:564–567. [PubMed: 15786469]

144. Autere J, Moilanen JS, Finnila S, Soininen H, et al. Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum. Genet 2004;115:29–35. [PubMed: 15108120]

145. Kirchner SC, Hallagan SE, Farin FM, Dilley J, et al. Mitochondrial ND1 sequence analysis and association of the T4216C mutation with Parkinson's disease. Neurotoxicology 2000;21:441–445. [PubMed: 11022854]

146. Huerta C, Castro MG, Coto E, Blazquez M, et al. Mitochondrial DNA polymorphisms and risk of Parkinson's disease in Spanish population. J. Neurol. Sci 2005;236:49–54. [PubMed: 15975594]

147. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, et al. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000;55:533–538. [PubMed: 10953187]

148. Langston JW, Ballard PA, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979–980. [PubMed: 6823561]

149. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci 2000;3:1301–1306. [PubMed: 11100151]

150. Schapira AHV, Cooper JM, Dexter D, Jenner P, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269. [PubMed: 2566813]

151. Bindoff LA, Birch-Machin M, Cartlidge NEF, Parker WDJ, et al. Mitochondrial function in Parkinson's disease. Lancet 1989;2:49. [PubMed: 2567823]

152. Parker WD Jr, Boyson SJ, Parks JK. Electron transport chain abnormalities in idiopathic Parkinson's disease. Ann. Neurol 1989;26:719–723. [PubMed: 2557792]

153. Schapira AH. Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ 2007;14:1261–1266. [PubMed: 17464321]

154. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, et al. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol 1996;40:663–671. [PubMed: 8871587]

155. Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J. Neurosci. Res 2007;85:3416–3428. [PubMed: 17243174]

156. Swerdlow RH, Parks JK, Davis JN, Cassarino DS, et al. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann. Neurol 1998;44:873–881. [PubMed: 9851431]

157. Maceluch JA, Niedziela M. The clinical diagnosis and molecular genetics of Kearns–Sayre syndrome: A complex mitochondrial encephalomyopathy. Pediatr. Endocrinol. Rev 2007;4:117–137. [PubMed: 17342029]

158. Thambisetty M, Newman NJ. Diagnosis and management of MELAS. Expert Rev. Mol. Diagn 2004;4:631–644. [PubMed: 15347257]

159. DiMauro S, Hirano M, Kaufmann P, Tanji K, et al. Clinical features and genetics of myoclonic epilepsy with ragged red fibers. Adv. Neurol 2002;89:217–229. [PubMed: 11968448]

160. Holt IJ, Harding AE, Petty RKH, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am. J. Hum. Genet 1990;46:428–433. [PubMed: 2137962]

161. Yen MY, Wang AG, Wei YH. Leber's hereditary optic neuropathy: A multifactorial disease. Prog. Retin. Eye Res 2006;25:381–396. [PubMed: 16829155]

162. Silvestri G, Servidei S, Rana M, Ricci E, et al. A novel mitochondrial DNA point mutation in the tRNAIle gene is associated with progressive external ophthalmoplegia. Biochem. Biophys. Res. Comm 1996;220:623–627. [PubMed: 8607814]

163. Hosszufalusi N, Karcagi V, Horvath R, Palik E, et al. A detailed investigation of maternally inherited diabetes and deafness (MIDD) including clinical characteristics, C-peptide secretion, HLA-DR and -DQ status and autoantibody pattern. Diabetes Metab. Res. Rev 2009;25:127–135. [PubMed: 19116951]

164. Pal DK, Durner M, Klotz I, Dicker E, et al. Complex inheritance and parent-of-origin effect in juvenile myoclonic epilepsy. Brain Dev 2006;28:92–98. [PubMed: 16414227]

165. Eapen V, O'Neill J, Gurling HM, Robertson MM. Sex of parent transmission effect in Tourette's syndrome: Evidence for earlier age at onset in maternally transmitted cases suggests a genomic imprinting effect. Neurology 1997;48:801–802. [PubMed: 9109857]

166. Horsthemke B, Wagstaff J. Mechanisms of imprinting of the Prader–Willi/Angelman region. Am. J. Med. Genet 2008;146:2041–2052. [PubMed: 18627066]

167. Cook EH Jr, Lindgren V, Leventhal BL, Courchesne R, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am. J. Hum.Genet 1997;60:928–934. [PubMed: 9106540]

168. Brown MD, Starikovskaya E, Derbeneva O, Hosseini S, et al. The role of mtDNA background in disease expression: A new primary LHON mutation associated with Western Eurasian haplogroup. J. Hum. Genet 2002;110:130–138.

169. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2001;98:11039–11041. [PubMed: 11572965]

170. Bothwell M, Giniger E. Alzheimer's disease: Neurodevelopment converges with neurodegeneration. Cell 2000;102:271–273. [PubMed: 10975517]

171. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;457:981–989. [PubMed: 19225519]

**Figure 1.**
Incidence of AD cases in the USA. State-specific projections up to 2025 (adapted from Hebert *et al.*[2]).

**Figure 2.**
Statistical parametric maps showing reduced brain glucose metabolism in cognitively normal individuals with a maternal history of AD (FHm) compared with those with a paternal history of AD (FHp, in red) and with those with no family history of AD (FH–, in green).[7] Brain regions showing hypometabolism in FHm compared with FHp and FH– include the inferior parietal lobes, lateral and inferior temporal cortex, posterior cingulate/precuneus and dorsolateral prefrontal cortex. These same brain regions are typically hypometabolic in clinical AD patients. Figure shows the superior, posterior, right and left lateral views of a three-dimensional volume-rendered MRI.

**Figure 3.**
Statistical parametric maps showing CMRglc reductions over a two-year follow-up interval. Compared with the baseline, reduced follow-up CMRglc was restricted to the frontal cortices in normal subjects with no family history of AD (top row, in green) and in those with an AD father (middle row, in blue), whereas follow-up CMRglc was reduced in inferior parietal, lateral and inferior temporal, posterior cingulate/precuneus and prefrontal cortex in normal individuals with a maternal history of AD (bottom row, in red). Figure shows the anterior, right lateral, superior and mid-sagittal views of a three-dimensional volume-rendered MRI.

**Figure 4.**
^{18}F-FDG PET scans of two cognitively normal (NL) individuals with postmortem-confirmed AD parents. The ^{18}F-FDG PET of the son of an AD father (left) shows no CMRglc abnormalities, while the ^{18}F-FDG PET of the daughter of an AD mother (right) shows areas of reduced CMRglc (indicated by arrows).[7] CMRglc measures are represented on a colour-coded scale, ranging from 0 to 60 μmol glucose/100 g/min (right side of figure).

**Figure 5.**
The cybrid technique (adapted from Kish *et al.*[114]). The procedure involves obtaining mtDNA from persons with and without disease. Usually, platelets are used as the mtDNA donor tissue, since platelets are easily obtained through standard phlebotomy, are easy to isolate through centrifugation and lack nuclei. Mixing platelets with cell lines depleted of their own endogenous mtDNA allows exchange of platelet and cell line materials, which results in cell lines containing mtDNA from the individual platelet donors. These cell lines expand under standard culture conditions, and their biochemical assessment allows investigators to evaluate parameters directly or indirectly referable to mitochondria and the mtDNA they carry. Differences in mtDNA lead to differences in the mtDNA-encoded subunits of oxidative phosphorylation complexes I, III, IV and V. Functional differences between cybrid cell lines should reflect differences in mtDNA that cause changes in these enzyme complexes.

**Table 1**

Genes associated with Alzheimer's disease

| Gene | Chromosome | Transmission | AD form | Prevalence | Clinical characteristics | *In vivo* imaging findings |
|------|-----------|--------------|---------|-----------|--------------------------|----------------------------|
| *APP* | 21 | Autosomal dominant | EOFAD | 10–15% of EOFAD | Age of onset <65 years Increased processing of APP to A$\beta_{42}$ | Reduced CMRglc on FDG-PET in pre-symptomatic and symptomatic mutation carriers |
| *APP* | 21 | Autosomal recessive | EOFAD | na | Age of onset <50 years Increased A$\beta$ production | na |
| *PSEN1* | 14 | Autosomal dominant | EOFAD | 30–70% of EOFAD | Age of onset 40–50 years Increased processing of APP to A$\beta_{42}$ Rapid progression Associated with seizures, myoclonus and language deficits | Reduced CMRglc on FDG-PET and striatal amyloid deposition on PIB PET in pre-symptomatic and symptomatic mutation carriers |
| *PSEN2* | 1 | Autosomal dominant | EOFAD | <5% of EOFAD | Age of onset 40–70 years Increased A$\beta_{42}$ production | na |
| *ApoE* | 19 | 3 allelic variants: ε2, ε3, ε4 | LOAD | 40% of LOAD, 10–20% of controls | ApoE ε4 carriers *vs* non-carriers show lower age at onset, reduced A$\beta$ clearance, poorer cognitive performance in late life | Hippocampal atrophy on MRI and reduced CMRglc on FDG-PET in pre-symptomatic and symptomatic *ApoE ε4* carriers *vs* non-carriers |
| *SORL1* | 11 | SNPs: 8–10 and 22–25 gene regions | LOAD | 20–40% of LOAD | Increased A$\beta$ production | Hippocampal atrophy on MRI in *SORL1* carriers *vs* non-carriers |
| *KIBRA* | 5 | SNP: T → C | LOAD | 45% of LOAD | Poorer episodic memory in *CC* carriers vs *TT* and *TC* carriers | Increased hippocampal activation on fMRI, and reduced CMRglc on FDG-PET in *CC* carriers *vs CT* and *TT* carriers |
| *GAB2* | 11 | 6 SNPs | LOAD | 70% of LOAD | CT–AAG–CAGATCAGACG vs TC–GCA–TGAGGTGTCTT haplotype: Less protection from neuronal tangle formation and cell death Increased risk of AD | na |

| Gene | Chromosome | Transmission | AD form | Prevalence | Clinical characteristics | *In vivo* imaging findings |
|------|-----------|--------------|---------|-----------|--------------------------|----------------------------|
| *PCDH11X* | X | SNP: Rs5984894 | LOAD | na | Increased risk of AD | na |

EOFAD = early onset familial Alzheimer's disease; CMRglc = cerebral metabolic rate of glucose; na = not available; FDG-PET = fluoro-2-deoxy-D-glucose positron emission tomography; PIB-PET = Pittsburgh Compound-B PET; LOAD = late onset AD; MRI = magnetic resonance imaging

**Table 2**

Prevalence of maternally vs paternally inherited late-onset Alzheimer's disease (AD)

| Reference | AD cases | No affected parents | FH− | FHm | FHp | Mother:father ratio |
|-----------|----------|---------------------|-----|-----|-----|---------------------|
| Heyman et al.[81] | 68 | 11 | 84% | 10% | 6% | 1.8:1 |
| Duara et al.[77] | 311 | 69 | 78% | 17% | 5% | 3.6:1 |
| Edland et al.[78] | 118 | 24 | 80% | 16% | 4% | 3.8:1 |
| Farrer et al.[70] | 251 | 61 | 76% | 16% | 8% | 1.9:1 |
| Gomez-Tortosa et al.[80] | 2594 | 817 | 68% | 23% | 9% | 2.6:1 |

FH− = No family history of AD; FHm = maternal history of AD; FHp = paternal history of AD.

**Table 3**

Mitochondrial DNA mutations and haplotypes associated with late-onset AD

| Approach | Finding | Positive findings | Negative findings |
|---|---|---|---|
| Case-control mutation identification | T146G, T195C, T152C, A189G, T414G | Increased AD risk[121] | No mutation found[122] |
| | 4977 bp deletion | More frequent in AD patients[123] | |
| | A4336G | More frequent in AD patients[124,125] | No association with AD[126] |
| Haplogroup association | K, U | Decreased risk of AD, neutralising the effect of *ApoE* genotype[127] | No effect of K haplogroup in AD[128] |
| | U | Increased risk in males, decreased risk in females[128] | |
| | J | Increased in AD patients in a French-Canadian population[129] | No AD haplogroup association in US population[122] |
| | T | Decreased AD risk in a French-Canadian population[129] | No AD haplogroup association in US population[122] |

bp = base pair

**Table 4**

Mitochondrial DNA mutations and haplotypes associated with Parkinson's disease (PD)

| mtDNA haplogroup or mutation | Hypothesised role | Reference |
|---|---|---|
| Haplogroup J, K | Lower PD risk | Van der Walt et al.[142] |
| UKJT haplogroup supercluster | Lower PD risk | Pyle et al.[143] |
| JTIWX haplogroup supercluster | Higher PD and PD with dementia risk | Autere et al.[144] |
| Haplogroup I, J, K | Decreased risk for PD but increased risk for PD with dementia | Autere et al.[144] |
| mtDNA mutation: 10398G (J, K, I haplogroups) | Lower PD risk | Van der Walt et al.;[142] Autere et al.[144] |
| mtDNA mutation: 9055A | Lower PD risk (only in women) | Van der Walt et al.[142] |
| mtDNA mutation: 4216C (*ND1* gene) | Increased PD risk | Kirchner et al.[145] |
| mtDNA mutation: 4216C (*ND1* gene) | No difference observed | Huerta et al.[146] |
| mtDNA mutation: 4336 (tRNA$^{glu}$) | More frequent in PD patients | Tan et al.[147] |

**Table 5**

Medical and neurological disorders with known or suspected maternal inheritance

| Disorder | Mechanism | Clinical phenotype | Reference |
|---|---|---|---|
| Kearns–Sayre syndrome | mtDNA deletions present at levels up to 80% of total mtDNA. The most frequent is 4977 bp deletion | Paralysis of the extraocular muscles, pigmentary retinopathy, heart block, cerebellar ataxia and elevated CSF proteins | Maceluch et al.[157] |
| Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) | mtDNA mutation: A3243G (tRNA$^{Leu(UUR)}$) | Children and young adults. Recurrent vomiting, migraine-like headache, stroke-like episodes causing cortical blindness, hemiparesis or hemianopia | Thambisetty et al.[158] |
| Myoclonic epilepsy with ragged red fibres (MERRF) | mtDNA mutation: A8344G, T8356C, G8363A (tRNA$^{Lys}$) | Myclonus, seizures, mitochondrial myopathy and cerebellar ataxia; less common signs can include dementia, hearing loss, peripheral neuropathy and multiple lipomas | DiMauro et al.[159] |
| Neuropathy, ataxia, retinitis pigmentosa (NARP) | mtDNA mutation: T8993G, T8993C (nt–8993 at the ATPase6 gene) | Retinitis pigmentosa, dementia, seizures, ataxia, proximal weakness and sensory neuropathy | Holt et al.[160] |
| Maternally inherited Leigh syndrome (MILS) | mtDNA mutation: T8993G, T8993C (nt–8993 at the ATPase6 gene) | Symmetrical lesions in the basal ganglia and the brainstem | Holt et al.[160] |
| Leber's hereditary optic neuropathy (LHON) | mtDNA mutation: G11778A (ND4 gene), G3460A (ND1 gene), T14484C (ND6 gene) | Acute or subacute loss of vision in young adults due to bilaterally optic neuropathy | Yen et al.[161] |
| Progressive external ophthalmoplegia (PEO) | mtDNA mutation in genes encoding tRNA$^{Leu}$, tRNA$^{Ile}$ and tRNA$^{Asn}$ | Progressive paralysis of the extraocular muscles | Silvestri et al.[162] |
| Maternally inherited diabetes and deafness (MIDD) | mtDNA mutation: A3243G (tRNA$^{Leu}$) | Impaired glucose tolerance (IGT)/diabetes, sensorineural deafness. Other symptoms are: macular pattern dystrophy (86%), myopathy (43%), cardiomyopathy (15%), neurological abnormalities and neuropsychiatric symptoms (18%), gastrointestinal and renal dysfunction | Hosszufalusi et al.[163] |
| Juvenile myoclonic epilepsy | Genomic imprinting: EJM–1 (chromosome 6) | Seizures | Pal et al.[164] |
| Tourette's syndrome | Genomic imprinting | Multiple physical (motor) and vocal (phonic) tics | Eapen et al.[165] |

| Disorder | Mechanism | Clinical phenotype | Reference |
|---|---|---|---|
| Angelman syndrome | Genomic imprinting (chromosome 15) | Intellectual and developmental delay, sleep disturbance, seizures, jerky movements, frequent laughter or smiling and usually a happy demeanour | Horsthemke et al.[166] |
| Autism | Genomic imprinting (chromosome 15) | Autism | Cook et al.[167] |
| Fragile X syndrome | Unstable expansions of a CGG trinucleotide repeat located in the first exon (non-protein-coding) of the FMR1 gene (for fragile X mental retardation) | Stereotypic movements and atypical social development up to autism. Cluttered or nervous speech; intellectual disability (from mild to severe); elongated face, large or protruding ears, flat feet and low muscle tone | Mandel et al.[132] |
| Friedreich ataxia | GAA repeat expansion (chromosome 9) | Ataxia, gait disturbance, speech problems, heart disease (in some cases) | La Pean et al.[133] |
| Myotonic dystrophy | CTG repeat expansion | Muscle weakness, cataract, myotonia, infertility | Botta et al.[134] |

bp = base pair; CSF = cerebrospinal fluid